Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2003
11/18/2003US6649386 Stability; for reconstitution with water; antihemophilic factor; blood factor IX
11/18/2003US6649385 Isolated nucleic acid molecules encoding human squalene synthase proteins, and related products and processes
11/18/2003US6649374 Recombinant Chlamydia trachomatis PGP3 antigen
11/18/2003US6649373 Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene
11/18/2003US6649371 Isolated nucleic acid molecule; using transformed cells for screening compounds for inhibiting or activating activity
11/18/2003US6649370 Isolated polynucleotide which induces a immune response when administered to a mammal; expression vectors; vaccines
11/18/2003US6649364 Anti-apoptotic compositions and methods using same
11/18/2003US6649362 Administering an agent to modulate sphingosine kinase signalling pathway to treat coronary heart disease
11/18/2003US6649345 Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
11/18/2003US6649344 Testing sample for the presence and concentration of hormones, lipids, nucleic acids, intracellular messengers or enzymes; in vitro maturation and fertilization; inhibin A; estradiol
11/18/2003US6649340 Protein which contains a predetermined amino acid in the hypervariable region of the antigen-binding site; use in studying structure/ function and in developing new enzymes and antibodies
11/18/2003US6649339 Screening for the presence of a parvovirus genome equivalent using nucleic acid amplification; purification
11/18/2003US6649189 Screening activities of eukaryotic tissues; obtain sample tissue, incubate with modulator, monitor cellular activity of tissues
11/18/2003US6649168 Pharmaceutical compositions comprising TGF-beta
11/18/2003US6649165 Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble FcγRIII receptors
11/18/2003US6649164 (RANK); RANK is a member of the TNF superfamily; used to regulate an immune response
11/18/2003US6649161 Administering neurotoxin
11/18/2003US6649157 Treating a Ras-mediated cell proliferative disorder in a mammal, by administering a modified adenovirus, modified HSV, modified vaccinia virus or modified parapoxvirus orf virus resulting in lysis of the proliferating cells.
11/18/2003US6647987 Insulin delivery enhanced by coached breathing
11/18/2003CA2276109C Peptidomimetic inhibitors of the human cytomegalovirus protease
11/18/2003CA2265508C Bone morphogenetic protein-16 (bmp-16) compositions
11/18/2003CA2223433C Ob protein compositions and methods
11/18/2003CA2109952C Pharmaceutical compositions
11/18/2003CA2045208C Inhibition of coloration of human serum albumin
11/18/2003CA1341447C Mutant t-pa with kringle replacement
11/18/2003CA1341446C Tissue plasminogen activator analogs having modified growth factor domains
11/13/2003WO2003093830A1 Diagnostics and therapeutics for diseases associated with neuromedin b receptor (nmb)
11/13/2003WO2003093829A1 Diagnostics and therapeutics for diseases associated with neurotensin receptor 2 (nt2)
11/13/2003WO2003093828A1 Diagnostics and therapeutics for diseases associated with neurotensin receptor 1 (nt1)
11/13/2003WO2003093816A2 Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
11/13/2003WO2003093793A2 Binary or polynary targeting and uses thereof
11/13/2003WO2003093503A2 Method for bioequivalence determination using expression profiling
11/13/2003WO2003093485A2 Optimization of transgene expression in mammalian cells
11/13/2003WO2003093480A2 Immortalized hypothalamic neuronal cell lines
11/13/2003WO2003093478A1 Immunoconjugates for the treatment of tumours
11/13/2003WO2003093476A1 Vector with modified protease-dependent tropism
11/13/2003WO2003093473A1 A multimeric self-cleaving ribozyme construct
11/13/2003WO2003093465A1 FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
11/13/2003WO2003093452A2 Variants of nedd4l associated with hypertension and viral budding
11/13/2003WO2003093449A2 Methods for delivery of nucleic acids
11/13/2003WO2003093432A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
11/13/2003WO2003093431A2 Ablated slam-dependent entry
11/13/2003WO2003093422A2 Novel tissue factor targeted antibodies as anticoagulants
11/13/2003WO2003093421A2 Methods and compositions for use in homologous recombination
11/13/2003WO2003093419A2 Preventing secondary lymphedema with vegf-d dna
11/13/2003WO2003093320A2 Antibodies specific for human cd22 and their therapeuatic and digagnostic uses
11/13/2003WO2003093314A2 Connective tissue stimulating peptides
11/13/2003WO2003093313A2 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
11/13/2003WO2003093311A1 Proteins with deglycating activities and methods of using same
11/13/2003WO2003093310A1 Novel nucleic acid sequences and proteins of tumors and neoplasias of the thyroid gland
11/13/2003WO2003093308A1 Metallo proteinase inhibitory agent
11/13/2003WO2003093305A2 Teneurin c-terminal associated peptides (tcap) and uses thereof
11/13/2003WO2003093304A1 Agonists and antagonists of gonadotropin-releasing hormone-2, and use thereof
11/13/2003WO2003093303A1 Targeting proteins to deliver therapeutic or diagnostic reagents
11/13/2003WO2003093300A2 Anti-microbial peptides and compositions
11/13/2003WO2003093299A2 Insulin-associated peptides with effects on cerebral health
11/13/2003WO2003093294A2 Conformationally constrained peptides that bind the orl-1 receptor
11/13/2003WO2003093293A2 Peptide antagonists of tgf-beta family members and therapeutic uses thereof
11/13/2003WO2003093291A2 Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
11/13/2003WO2003092737A1 Fusions of cytokines and tumor targeting proteins
11/13/2003WO2003092735A2 Peptide nucleic acid conjugates with beta-amino acid polymers or reptoids
11/13/2003WO2003092733A1 Chemically activated carboxypolysaccharides and uses
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092731A1 Stabilised solid compositions of modified factor vii
11/13/2003WO2003092727A1 Medical device
11/13/2003WO2003092726A1 Combination of insulin and a thiazolidinedione derivative, and use thereof for treating diabetes
11/13/2003WO2003092725A1 Method for control of depression using c terminal growth hormone (gh) fragment
11/13/2003WO2003092724A1 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
11/13/2003WO2003092723A1 Use of fasl for the treatment of neurodegenerative diseases
11/13/2003WO2003092721A1 A combination product comprising melagatran and an anti-arrhythmic oxabispidenes
11/13/2003WO2003092720A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
11/13/2003WO2003092719A2 Methods and compositions for modulating beta-catenin phosphorylation
11/13/2003WO2003092718A2 Treatment and inhibition of ocular infections and wounds by cap37 and cap37 peptides
11/13/2003WO2003092716A2 Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
11/13/2003WO2003092715A2 Proteins involved in the regulation of energy homeostasis
11/13/2003WO2003092711A1 Method of enhancing biological activity of plant extracts
11/13/2003WO2003092708A1 Antitumor agents with the use of hsv
11/13/2003WO2003092705A1 Diagnosis and treatment of glaucoma and methods for discovering new glaucoma therapeutic agents based on the wnt/ca2+ signaling pathway
11/13/2003WO2003092687A1 Methods of modulating smooth muscle contractility
11/13/2003WO2003092684A1 TIME-RESOLVED FLUORESCENCE ASSAY FOR THE DETECTION OF MULTIMERIC FORMS OF A-β[BETA] OR OTHER AGGREGATING POLYPEPTIDES
11/13/2003WO2003092671A1 Method of inhibiting angiogenesis
11/13/2003WO2003092657A1 Microparticles bearing cells and active substances
11/13/2003WO2003092647A2 Transport system in biological systems
11/13/2003WO2003092632A2 Cyclic peptide anti-cancer agents and methods
11/13/2003WO2003092631A2 Cyclic peptide anti-viral agents and methods
11/13/2003WO2003092624A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003WO2003092618A2 Materials and methods for prevention and treatment of rna viral diseases
11/13/2003WO2003092614A2 Lipid removal from the body
11/13/2003WO2003092612A2 VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE
11/13/2003WO2003092611A2 Methods of inducing formation of functional and organized lymphatic vessels
11/13/2003WO2003092610A2 Methods of using cytokine antagonists to treat hiv infection and aids
11/13/2003WO2003092608A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003WO2003092605A2 Protease inhibitors
11/13/2003WO2003092603A2 Composition and method for reducing post-prandial blood glucose
11/13/2003WO2003092602A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003WO2003092598A2 Treatment for pompe disease
11/13/2003WO2003092595A2 Tyrosine kinase inhibitors
11/13/2003WO2003092594A2 Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
11/13/2003WO2003092593A2 Tumor suppressor gene polypeptides
11/13/2003WO2003092592A2 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
1 ... 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 ... 3163